Diaplant: Manufacturing technology and rationalization of costs of acute intestinal infection pharmacotherapy

Abstract

Aim: To the development of the technological scheme of a new drug Diaplant, and rationalization of the costs of the acute intestinal infection (AII) pharmacotherapy. Materials and Methods: Development of the technological scheme of the new drug in tablets called Diaplant; analysis of the Ukraine pharmaceutical market of the analogs of Diaplant; pharmacoeconomic advantages of Diaplant compared with its analogs. Results and Discussion: In the pharmaceutical market of Ukraine, there are groups Ð07 antidiarrheals, intestinal anti-inflammatory/anti-infective agents according to Anatomical Therapeutic Chemical (ATC)-classification. ATC/defined daily dose (DDD)-analysis showed that the cost for DDD of Diaplant was 9.60 UAH. The total cost of the average recommended daily doses of separate drugs (nifuroxazide and plantaglucidum) ranged from 14 to 27.42 UA. The use of the drug Diaplant for the treatment 1000 patients requires 9600 UAH daily and 288000 UAH monthly. The use of other drugs with nifuroxazide and plantaglucidum requires from 14000 to 27420 UAH daily and from 420,000 to 822,600 UAH monthly. Savings of financial resources can be from 4400 to 17,820 UAH/day and – from 132,000 to 534,600 UAH/month for 1000 patients receiving Diaplant. It has been found that the Diaplant can provide the treatment from 1460 to 2860 patients instead of only 1000 patients receiving its analogs at the pharmaceutical market of Ukraine. Conclusion: The technological scheme of production of the drug in capsules Diaplant that contains nifuroxazide and plantaglucidum were developed for pharmacotherapy of AIIs. The use of Diaplant in clinical practice allows reducing the cost of pharmacotherapy from 46% to 286%.